Otsuka Company Profile
✉ Email this page to a colleague
What is the competitive landscape for OTSUKA, and when can generic versions of OTSUKA drugs launch?
OTSUKA has seventeen approved drugs.
There are fifty-six US patents protecting OTSUKA drugs.
There are one thousand and seventeen patent family members on OTSUKA drugs in fifty-four countries and forty-nine supplementary protection certificates in sixteen countries.
Summary for Otsuka
International Patents: | 1017 |
US Patents: | 56 |
Tradenames: | 15 |
Ingredients: | 10 |
NDAs: | 17 |
Patent Litigation for Otsuka: | See patent lawsuits for Otsuka |
Drugs and US Patents for Otsuka
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Otsuka | ABILIFY MYCITE KIT | aripiprazole | TABLET;ORAL | 207202-001 | Nov 13, 2017 | RX | Yes | No | 8,847,766 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Otsuka | ABILIFY MYCITE KIT | aripiprazole | TABLET;ORAL | 207202-002 | Nov 13, 2017 | RX | Yes | Yes | 11,464,423 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Otsuka | REXULTI | brexpiprazole | TABLET;ORAL | 205422-002 | Jul 10, 2015 | AB | RX | Yes | No | 8,349,840 | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||
Otsuka Pharm Co Ltd | ABILIFY MAINTENA KIT | aripiprazole | FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 202971-002 | Feb 28, 2013 | RX | Yes | Yes | 8,399,469 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Otsuka | REXULTI | brexpiprazole | TABLET;ORAL | 205422-001 | Jul 10, 2015 | AB | RX | Yes | No | 8,618,109 | ⤷ Try a Trial | ⤷ Try a Trial | |||
Otsuka | ABILIFY MYCITE KIT | aripiprazole | TABLET;ORAL | 207202-006 | Nov 13, 2017 | RX | Yes | No | 9,060,708 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Otsuka
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Otsuka | ABILIFY MYCITE KIT | aripiprazole | TABLET;ORAL | 207202-002 | Nov 13, 2017 | 8,642,760 | ⤷ Try a Trial |
Otsuka America | MERETEK UBT KIT (W/ PRANACTIN) | urea c-13 | FOR SOLUTION;ORAL | 020586-001 | Sep 17, 1996 | 4,830,010 | ⤷ Try a Trial |
Otsuka | ABILIFY | aripiprazole | SOLUTION;ORAL | 021713-001 | Dec 10, 2004 | 7,053,092 | ⤷ Try a Trial |
Otsuka | ABILIFY | aripiprazole | TABLET;ORAL | 021436-003 | Nov 15, 2002 | 7,053,092 | ⤷ Try a Trial |
Otsuka Pharm | BUSULFEX | busulfan | INJECTABLE;INJECTION | 020954-001 | Feb 4, 1999 | 5,430,057*PED | ⤷ Try a Trial |
Otsuka | ABILIFY | aripiprazole | TABLET;ORAL | 021436-003 | Nov 15, 2002 | 9,387,182 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for OTSUKA drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Tablets | 15 mg and 30 mg | ➤ Subscribe | 2013-09-23 |
➤ Subscribe | Injection | 6 mg/mL | ➤ Subscribe | 2012-12-26 |
➤ Subscribe | Oral Solution | 1 mg/mL | ➤ Subscribe | 2007-12-20 |
➤ Subscribe | Orally Disintegrating Tablets | 10 mg, 15 mg, 20 mg and 30 mg | ➤ Subscribe | 2006-11-15 |
➤ Subscribe | Tablets | 60 mg | ➤ Subscribe | 2018-03-26 |
➤ Subscribe | Tablets | 2 mg, 5 mg, 10 mg, 15 mg, 20 mg and 30 mg | ➤ Subscribe | 2006-11-15 |
International Patents for Otsuka Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Argentina | 046141 | ⤷ Try a Trial |
Canada | 3030268 | ⤷ Try a Trial |
Israel | 227364 | ⤷ Try a Trial |
Eurasian Patent Organization | 201491685 | ⤷ Try a Trial |
Argentina | 122575 | ⤷ Try a Trial |
Australia | 2006237905 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Otsuka Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1869025 | 32/2018 | Austria | ⤷ Try a Trial | PRODUCT NAME: BREXPIPRAZOL ODER EIN SALZ DAVON; REGISTRATION NO/DATE: EU/1/18/1294 (MITTEILUNG) 20180727 |
1869025 | LUC00086 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: BREXPIPRAZOLE OU UN SEL DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/18/1294 20180730 |
0450097 | 09C0049 | France | ⤷ Try a Trial | PRODUCT NAME: TOLVAPTAN, EVENTUELLEMENT SOUS FORME DE SEL; REGISTRATION NO/DATE: EU/1/09/539/001 20090803 |
0367141 | SPC/GB04/039 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: ARIPIPRAZOLE OR A SALT THEREOF; REGISTERED: UK EU/1/04/276/001 20040604; UK EU/1/04/276/002 20040604; UK EU/1/04/276/003 20040604; UK EU/1/04/276/004 20040604; UK EU/1/04/276/005 20040604; UK EU/1/04/276/006 20040604; UK EU/1/04/276/007 20040604; UK EU/1/04/276/008 20040604; UK EU/1/04/276/009 20040604; UK EU/1/04/276/010 20040604; UK EU/1/04/276/011 20040604; UK EU/1/04/276/012 20040604; UK EU/1/04/276/013 20040604; UK EU/1/04/276/014 20040604; UK EU/1/04/276/015 20040604; UK EU/1/04/276/016 20040604; UK EU/1/04/276/017 20040604; UK EU/1/04/276/018 20040604; UK EU/1/04/276/019 20040604; UK EU/1/04/276/020 20040604 |
2207786 | 122023000069 | Germany | ⤷ Try a Trial | PRODUCT NAME: ZUSAMMENSETZUNG UMFASSEND: CEDAZURIDIN ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON; UND DECITABIN; REGISTRATION NO/DATE: EU/1/23/1756 20230915 |
1675573 | 92427 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: ARIPIPRAZOLE |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.